GICS Sector : Healthcare
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases.Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver.The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver.
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
Jul -25
Lilly and Verve announce expiration of Verve tender offer
Jul -24
3 Bullish Biotech Stocks With Explosive Growth Trends
Jul -21
Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week
Jun -20
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Verve Therapeutics, Inc. (NASDAQ: VERV)
Jun -20
VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV
Jun -19
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement
Jun -18
Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly
Jun -17
Verve Therapeutics' 14.17% growth is driven by increasing demand for gene editing therapies, strategic partnerships, and a strong pipeline of novel treatments for cardiovascular diseases. The company's proprietary gene editing platform, combined with its experienced management team, positions it for continued growth in the pharmaceutical segment.
VERVE-101 is an investigational, one-time gene editing treatment for heterozygous familial hypercholesterolemia (HeFH). It is designed to edit the PCSK9 gene and reduce LDL cholesterol levels.
VERVE-201 is an investigational, one-time gene editing treatment for homozygous familial hypercholesterolemia (HoFH). It is designed to edit the LDLR gene and reduce LDL cholesterol levels.
VERVE-301 is an investigational, one-time gene editing treatment for atrial fibrillation. It is designed to edit the SCN10A gene and reduce the risk of atrial fibrillation.
Verve Therapeutics, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for cardiovascular diseases.
Verve Therapeutics, Inc. has a low bargaining power of customers due to the lack of negotiating power among patients and healthcare providers.
Verve Therapeutics, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers for raw materials and services.
Verve Therapeutics, Inc. has a high threat of new entrants due to the growing interest in gene editing technologies and the potential for new companies to enter the market.
Verve Therapeutics, Inc. operates in a highly competitive market with several established players, leading to a high intensity of rivalry.
| Value | |
|---|---|
| Debt Weight | 11.11% |
| Debt Cost | 3.95% |
| Equity Weight | 88.89% |
| Equity Cost | 13.58% |
| WACC | 12.51% |
| Leverage | 12.49% |
Value: 6.8
Growth: 4.3
Quality: 5.0
Yield: 0.0
Momentum: 9.5
Volatility: 0.7
1-Year Total Return ->
Value: 6.2
Growth: 4.4
Quality: 4.3
Yield: 0.0
Momentum: 10.0
Volatility: 0.3
1-Year Total Return ->
Value: 9.6
Growth: 5.9
Quality: 3.5
Yield: 0.0
Momentum: 0.0
Volatility: 0.3
1-Year Total Return ->
Value: 8.0
Growth: 5.6
Quality: 4.8
Yield: 0.0
Momentum: 0.0
Volatility: 0.0
1-Year Total Return ->
Value: 6.6
Growth: 0.9
Quality: 4.0
Yield: 0.0
Momentum: 5.0
Volatility: 0.7
1-Year Total Return ->
Value: 6.0
Growth: 1.6
Quality: 3.5
Yield: 0.0
Momentum: 1.0
Volatility: 1.3
1-Year Total Return ->